Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL25950886 | 0.82 | PIN1 (0.46) | KDM4EALDH1A1GAAPIN1SMN1; SMN2 | |
| SCHEMBL25947639 | 0.81 | ALDH1A1 (0.38) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| Phosphine SCHEMBL25950907 | 0.79 | PIN1 (0.41) | MEN1KMT2AALDH1A1PIN1 | |
| SCHEMBL30183986 | 0.75 | KDM4E (0.37) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL29172306 | 0.75 | KDM4E (0.37) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL25947633 | 0.65 | PIN1 (0.46) | MEN1KMT2AALDH1A1PIN1SMN1; SMN2 | |
| Phosphine SCHEMBL24869500 | 0.64 | MAOB (0.59) | MEN1MAPTKMT2AALDH1A1HTT | |
| SCHEMBL30378947 | 0.64 | LCK (0.46) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL30635855 | 0.64 | PIN1 (0.64) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL3334570 | 0.64 | PIN1 (0.64) | KDM4EMEN1MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | KDM4E 1939/4885MEN1 2549/4885MAPT 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.